Highlights from

SPIN 2019

Skin Inflammation & Psoriasis International Network

Paris 25-27 April 2019

Switching infliximab biosimilars safe in treating chronic plaque psoriasis

Patients who switched between 2 different biosimilar infliximab products during treatment of chronic plaque psoriasis did not experience adverse events or change in severity [1]. In the study, 24 patients with psoriasis (12 of whom also had psoriatic arthritis) were switched from one infliximab biosimilar, CT-P13, to another, SB2. The patients, who had a previous exposure to CT-P13 of 23.2 (± 7.51) months, were then followed for 6 months after switching. Psoriasis Area and Severity Index (PASI) scores were measured at the time of the switch and at months 2, 4, and 6.

The investigators found that PASI scores at each measurement were substantially unchanged; mean scores at the time of the switch and at months 2, 4, and 6 were 0.67 (±1.38), 0.76 (±1.08), 0.71 (±0.93), and 0.42 (±0.62), respectively.

In terms of adverse events (AEs), in total, 2 infusion-related reactions, and 2 upper respiratory bacterial infections were observed. Despite the limited sample size and length of follow-up, the switch between the biosimilars, according to the researchers, was not associated with a statistically significant change in PASI score or with increased AEs.

Switching among multiple products is increasingly common in countries where single-winner tenders for biosimilars are undertaken and in which patients may be asked to transition among products regularly based on the winner of the tender. However, few data is available concerning switches among multiple biosimilars of the same reference compared with between 1 biosimilar and its reference. Thus, the data from this present study mark a contribution to the literature and may provide reassurance to prescribers who have concerns about the safety and efficacy of switching among multiple biosimilars.

  1. Gisondi P, Virga C, Girolomoni G. Cross-switch from CT-P13 to sb2 infliximab biosimilars in patients with chronic plaque psoriasis. Abstract P049, SPIN 2019, 25-27 April, Paris, France.

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.